{"contentid": 488054, "importid": NaN, "name": "Genevant nabs $600 million deal with Japan\u00e2\u0080\u0099s Takeda", "introduction": "Switzerland-based Genevant Sciences has entered into a global collaboration and license agreement with Japan\u00e2\u0080\u0099s largest drugmaker Takeda Pharmaceutical for the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis.", "content": "<p>Switzerland-based Genevant Sciences has entered into a global collaboration and license agreement with Japan&rsquo;s largest drugmaker Takeda Pharmaceutical (TYO: 4502) for the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis.</p>\n<p>Under the terms of the agreement, Genevant, a privately-held company of the Roivant family, is initially eligible to receive up to $600 million in upfront and milestone payments, plus royalties on future product sales. Takeda has exclusive rights to Genevant&rsquo;s LNP technology for a specified number of selected hepatic stellate cells targets.</p>\n<h2><strong>Adds to Gritstone deal</strong></h2>\n<p>This is the second out-licensing deal this year for Genevant, which in January entered into a collaboration of Gritstone Oncology to develop and commercialize self-amplifying RNA (SAM) vaccines against SARS-CoV-2, the virus that causes COVID-19, which could earn the Swiss firm as much as $192 million.&nbsp;</p>\n<p>&ldquo;It is well established that activated hepatic stellate cells are implicated in the progression of fibrotic liver disease, but unfortunately access to these cells has been elusive,&rdquo; said Pete Lutwyche, president and chief executive officer, Genevant Sciences Corp, adding: &ldquo;As longstanding leaders in nucleic acid delivery, Genevant has developed a novel hepatic stellate cell-directed LNP platform to meet this challenge and we are delighted to partner with Takeda to utilize this innovation to develop new treatments for patients suffering from liver fibrosis.&rdquo;</p>\n<p>&ldquo;Late-stage liver disease remains an area where new treatment options are desperately needed, so we are committed to exploring new and innovative approaches,&rdquo; said Bernard Allan, head of liver disease research at Takeda. &ldquo;The ability to target hepatic stellate cells with novel payloads leveraging Genevant&rsquo;s lipid nanoparticle technology is an exciting opportunity to discover and develop first-in-class therapies that we anticipate will halt or reverse the progression of liver fibrosis,&rdquo; he explained.</p>", "date": "2021-03-16 14:07:00", "meta_title": "Genevant nabs $600 million deal with Japan\u00e2\u0080\u0099s Takeda", "meta_keywords": "Genevant Sciences, Takeda, Roivant, License, Agreement, LNP-delivered, Liver fibrosis", "meta_description": "Genevant nabs $600 million deal with Japan\u00e2\u0080\u0099s Takeda", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-16 14:06:24", "updated": "2021-03-16 14:13:43", "access": NaN, "url": "https://www.thepharmaletter.com/article/genevant-nabs-600-million-deal-with-japan-s-takeda", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "roivant_logo_big.jpg", "image2id": "roivant_logo_small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Liver fibrosis", "sector_tag": "Biotechnology", "therapy area_tag": "Nephrology and Hepatology", "topic_tag": "Deals, Licensing, Research", "geography_tag": "Japan, Switzerland", "company_tag": "Genevant Sciences, Roivant Sciences, Takeda", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-16 14:07:00"}